ESPA revamped cancer immunotherapy triggered whole-body tumor destruction in early trials—shrinking cancers in half of patients and wiping them out entirely in two.
A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how it’s delivered—injecting it directly into tumors instead of into the bloodstream. In a small clinical trial of 12 patients with metastatic cancers, six saw their tumors shrink and two experienced complete remission.
A redesigned CD40 immunotherapy delivered directly into tumors triggered powerful immune responses in a small clinical trial, shrinking tumors in half the patients and eliminating cancer in two. Even tumors that weren’t injected disappeared, hinting that the treatment can spark a body-wide immune attack. Credit: AI/ScienceDaily.com
Know more: https://www.sciencedaily.com/releases/2026/03/260315225121.htm
